[Successful emergency operation for massive hemorrhage due to jejunal angiodysplasia after intensive chemotherapy in a patient with refractory anemia with excess of blasts].
A 59-year-old man was referred to our hospital because of pancytopenia. Peripheral blood examination showed a WBC of 1,500/microliters with 2% blasts, Hb 8.1 g/dl and a platelet count of 4.1 x 10(4)/microliters. A bone marrow aspiration revealed hyperplasia with proliferation of blasts (15.7%) and myelodysplasia. Chromosome analysis revealed multiple aberrations, including -5, -7, +8. The patient was given a diagnosis of refractory anemia with excess of blasts (RAEB) and treated with combination chemotherapy. Agranulocytosis and high fever remained after chemotherapy, and abdominal pain and diarrhea developed. An abdominal X-ray film and computed tomography scan demonstrated dilated small bowel, thickness of the bowel wall, and ascites. A diagnosis of neutropenic enterocolitis was given. During the WBC recovery period from nadir, massive hematochezia developed in the patient. Angiography detected the leakage of contrast medium from a peripheral region of the first jejunal artery into the jejunal lumen. A partial resection of the jejunum was thus performed, and a histological examination revealed the presence of irregularly dilated blood vessels in the submucosal layer. These findings were consistent with the features of angiodysplasia, and indicate that angiodysplasia should be considered one cause of intestinal hemorrhage in elderly patients during intensive chemotherapy.
Morita
K
K
Department of Internal Medicine, Suzuka Kaisel General Hospital.
Mizuno
T
T
Itoh
R
R
Suzuki
H
H
Tanaka
I
I
D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy*; D016888:Angiodysplasia / Q000139:chemically induced*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004630:Emergencies; D004760:Enterocolitis / Q000139:chemically induced; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000601:surgery; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects*; D007579:Jejunal Diseases / Q000139:chemically induced*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D003561:Cytarabine; D014750:Vincristine; D011239:Prednisolone; D015122:Mercaptopurine; D015255:Idarubicin; D003630:Daunorubicin